Online inquiry

IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4820MR)

This product GTTS-WQ4820MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in Psoriasis, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4820MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4544MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ14733MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ7849MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ9999MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ5252MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ4516MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ15803MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ4276MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW